© 2024 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Grace Halsey
Articles
Bempedoic Acid Reduced Risk for MACE by 30% in Primary Prevention Population: CLEAR Outcomes Subanalysis
June 27, 2023
ADA 2023: The only nonstatin therapy to reduce risk for 4-point MACE in ASCVD may potentially find a role in primary prevention as well, though caution is advised.
Triple Agonist Retatrutide Associated with Weight Loss of up to 24% in 48-Week Phase 2 Trial
June 27, 2023
ADA 2023: Weight loss with the combination GLP-1/GIP/glucagon receptor agonist was as high as 30% in study participants who received the highest dose.
Oral GLP-1 Agonist Orforglipron Leads to ~15% Mean Body Weight Reduction in Adults with Overweight/Obesity
June 26, 2023
ADA 2023: The investigational oral GLP-1 RA resulted in weight loss comparable to injectable GLP-1 RA formulations and requires no food or water restrictions.
Survodutide, Novel Dual GLP-1/Glucagon Agonist, Achieves ~19% Weight Loss in People with Overweight, Obesity
June 26, 2023
ADA 2023: Among survodutide-treated participants in a phase 2 study, more than half lost more than 50% of baseline bodyweight, reported PI Carel le Roux, MBChB, PhD.
SURMOUNT-2: Tirzepatide Treatment Leads to Average 15% Weight Loss in Adults with T2D, Obesity
June 24, 2023
ADA 2023: SURMOUNT-2 findings show tirzepatide is associated with greater weight loss in adults with T2D than any other treatment studied to date.
Friday's 5 Quotes for Primary Care
June 23, 2023
SGLT-2 inhibitors show broad cardiometabolic efficacy; colchicine approved for CV inflammation, astronomical diabetes rates; plus 2 more quotes of note.
Global Diabetes Prevalence Will Double by 2050, Affecting 1.3 Billion People: New Predictions
June 23, 2023
Type 2 diabetes will continue to comprise more than 90% of this population and obesity will be the primary driver, according to Global Burden of Disease researchers.
“Triagonist” Therapy for Type 2 Diabetes and Comorbidities to be Previewed at 2023 ADA Scientific Sessions
June 23, 2023
ADA 2023. Retatrutide, an investigational triple GLP-1/GIP/glucagon agonist, may provide benefits in liver fibrosis and obesity as well as in glycemic control.
SGLT-2 Inhibitor HF, CV Benefit Found Consistent Across Populations with T2D, CKD, HF
June 22, 2023
SGLT-2 inhibitors were found to consistently reduce risk of CV mortality and HF events in a meta-analysis including 90 000 high-risk patients with T2D, CKD, and/or HF.
Home Blood Pressure Monitoring among Older US Adults
June 22, 2023
Among adults aged 50 to 80 years with a BP-related condition, less than half say they regularly monitor BP at home; one-third are "not very concerned" about their BP.